Targeted drug trial aims to shrink lung tumors before surgery
NCT ID NCT07156604
Summary
This study is testing whether a drug called Vebreltinib can shrink tumors in patients with a specific genetic type of non-small cell lung cancer before they have surgery. The goal is to see if taking the drug for 8 weeks prior to an operation helps remove more of the cancer and improves long-term outcomes. The study will enroll about 30 patients who have not had prior targeted therapy for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.